-
1
-
-
84893594501
-
-
Centers for Disease Control and Prevention. Accessed July
-
Centers for Disease Control and Prevention. www.cdc.gov/ncbddd/hemophilia/data.html. Accessed July 2013.
-
(2013)
-
-
-
2
-
-
84872450786
-
Factor VIII products and inhibitor development in severe hemophilia A
-
PedNet and RODIN Study Group.
-
Gouw SC, van der Bom JG, Ljung R, Escuriola C, Cid AR, Claeyssens-Donadel S, van Geet C, Kenet G, Mäkipernaa A, Molinari AC, Muntean W, Kobelt R, Rivard G, Santagostino E, Thomas A, van den Berg HM; PedNet and RODIN Study Group. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med 2013; 368: 231-9.
-
(2013)
N Engl J Med
, vol.368
, pp. 231-239
-
-
Gouw, S.C.1
van der Bom, J.G.2
Ljung, R.3
Escuriola, C.4
Cid, A.R.5
Claeyssens-Donadel, S.6
van Geet, C.7
Kenet, G.8
Mäkipernaa, A.9
Molinari, A.C.10
Muntean, W.11
Kobelt, R.12
Rivard, G.13
Santagostino, E.14
Thomas, A.15
van den Berg, H.M.16
-
3
-
-
84893592106
-
-
World Federation of Hemophilia 2011. 4th edn. Accessed July
-
World Federation of Hemophilia 2011. Inhibitors in Hemophilia: A Primer. 4th edn. www1.wfh.org/publication/files/pdf-1122.pdf. Accessed July 2013
-
(2013)
Inhibitors in Hemophilia: A Primer
-
-
-
4
-
-
84866863644
-
Immune tolerance in haemophilia: the long journey to the fork in the road
-
DiMichele DM. Immune tolerance in haemophilia: the long journey to the fork in the road. Br J Haematol 2012; 159: 123-34.
-
(2012)
Br J Haematol
, vol.159
, pp. 123-134
-
-
DiMichele, D.M.1
-
5
-
-
79955139784
-
A retrospective study to describe the incidence of moderate to severe allergic reactions to factor IX in subjects with haemophilia B
-
Recht M, Pollmann H, Tagliaferri A, Musso R, Janco R, Neuman WR. A retrospective study to describe the incidence of moderate to severe allergic reactions to factor IX in subjects with haemophilia B. Haemophilia 2011; 17: 494-9.
-
(2011)
Haemophilia
, vol.17
, pp. 494-499
-
-
Recht, M.1
Pollmann, H.2
Tagliaferri, A.3
Musso, R.4
Janco, R.5
Neuman, W.R.6
-
6
-
-
35148857177
-
Factor eight inhibitor bypass activity (FEIBA) in the management of bleeds in hemophilia patients with high-titer inhibitors
-
Tjønnfjord GE, Holme PA. Factor eight inhibitor bypass activity (FEIBA) in the management of bleeds in hemophilia patients with high-titer inhibitors. Vasc Health Risk Manag 2007; 3: 527-31.
-
(2007)
Vasc Health Risk Manag
, vol.3
, pp. 527-531
-
-
Tjønnfjord, G.E.1
Holme, P.A.2
-
7
-
-
84893525238
-
-
® SMPC. Accessed July
-
® SMPC. www.medicines.org.uk/emc/medicine/21171/SPC/. Accessed July 2013
-
(2013)
-
-
-
8
-
-
74749095228
-
Bio-distribution of pharmacologically administered recombinant factor VIIa (rFVIIa)
-
Gopalakrishnan R, Hedner U, Ghosh S, Nayak RC, Allen TC, Pendurthi UR, Rao LV. Bio-distribution of pharmacologically administered recombinant factor VIIa (rFVIIa). J Thromb Haemost 2010; 8: 301-10.
-
(2010)
J Thromb Haemost
, vol.8
, pp. 301-310
-
-
Gopalakrishnan, R.1
Hedner, U.2
Ghosh, S.3
Nayak, R.C.4
Allen, T.C.5
Pendurthi, U.R.6
Rao, L.V.7
-
9
-
-
53449102958
-
Use of albumin fusion technology to prolong the half-life of recombinant factor VIIa
-
Schulte S. Use of albumin fusion technology to prolong the half-life of recombinant factor VIIa. Thromb Res 2008; 122(Suppl. 4): S14-9.
-
(2008)
Thromb Res
, vol.122
, Issue.SUPPL. 4
-
-
Schulte, S.1
-
10
-
-
43749102313
-
Prolonged in-vivo half-life of factor VIIa by fusion to albumin
-
Weimer T, Wormsbächer W, Kronthaler U, Lang W, Liebing U, Schulte S. Prolonged in-vivo half-life of factor VIIa by fusion to albumin. Thromb Haemost 2008; 99: 659-67.
-
(2008)
Thromb Haemost
, vol.99
, pp. 659-667
-
-
Weimer, T.1
Wormsbächer, W.2
Kronthaler, U.3
Lang, W.4
Liebing, U.5
Schulte, S.6
-
11
-
-
84866594053
-
Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients
-
Santagostino E, Negrier C, Klamroth R, Tiede A, Pabinger-Fasching I, Voigt C, Jacobs I, Morfini M. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood 2012; 120: 2405-11.
-
(2012)
Blood
, vol.120
, pp. 2405-2411
-
-
Santagostino, E.1
Negrier, C.2
Klamroth, R.3
Tiede, A.4
Pabinger-Fasching, I.5
Voigt, C.6
Jacobs, I.7
Morfini, M.8
-
12
-
-
0029011723
-
Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A
-
Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH Jr. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet 1995; 10: 119-21.
-
(1995)
Nat Genet
, vol.10
, pp. 119-121
-
-
Bi, L.1
Lawler, A.M.2
Antonarakis, S.E.3
High, K.A.4
Gearhart, J.D.5
Kazazian Jr, H.H.6
-
13
-
-
37249082059
-
Overview of the human pharmacokinetics of recombinant activated factor VII
-
Klitgaard T, Nielsen TG. Overview of the human pharmacokinetics of recombinant activated factor VII. Br J Clin Pharmacol 2007; 65: 3-11.
-
(2007)
Br J Clin Pharmacol
, vol.65
, pp. 3-11
-
-
Klitgaard, T.1
Nielsen, T.G.2
-
14
-
-
84855374941
-
Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial
-
1804 (adept(TM)1) Investigators
-
dePaula EV, Kavakli K, Mahlangu J, Ayob Y, Lentz SR, Morfini M, Nemes L, Šalek SZ, Shima M, Windyga J, Ehrenforth S, Chuansumrit A; 1804 (adept(TM)1) Investigators. Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial. J Thromb Haemost 2012; 10: 81-9.
-
(2012)
J Thromb Haemost
, vol.10
, pp. 81-89
-
-
de Paula, E.V.1
Kavakli, K.2
Mahlangu, J.3
Ayob, Y.4
Lentz, S.R.5
Morfini, M.6
Nemes, L.7
Šalek, S.Z.8
Shima, M.9
Windyga, J.10
Ehrenforth, S.11
Chuansumrit, A.12
-
15
-
-
84860457217
-
Phase I, randomized, double-blind, placebo-controlled, single-dose escalation study of the recombinant factor VIIa variant BAY 86-6150 in hemophilia
-
Mahlangu JN, Coetzee MJ, Laffan M, Windyga J, Yee TT, Schroeder J, Haaning J, Siegel JE, Lemm G. Phase I, randomized, double-blind, placebo-controlled, single-dose escalation study of the recombinant factor VIIa variant BAY 86-6150 in hemophilia. J Thromb Haemost 2012; 10: 773-80.
-
(2012)
J Thromb Haemost
, vol.10
, pp. 773-780
-
-
Mahlangu, J.N.1
Coetzee, M.J.2
Laffan, M.3
Windyga, J.4
Yee, T.T.5
Schroeder, J.6
Haaning, J.7
Siegel, J.E.8
Lemm, G.9
-
16
-
-
0019191269
-
The thrombogenicity of prothrombin complex concentrates: II. The effect of thrombocytopenia on in vivo thrombogenicity in rabbits
-
Giles AR, Hoogendoorn H, Blajchman MA, Hirsh J. The thrombogenicity of prothrombin complex concentrates: II. The effect of thrombocytopenia on in vivo thrombogenicity in rabbits. Thromb Res 1980; 17: 555-60.
-
(1980)
Thromb Res
, vol.17
, pp. 555-560
-
-
Giles, A.R.1
Hoogendoorn, H.2
Blajchman, M.A.3
Hirsh, J.4
-
17
-
-
79251554994
-
Recombinant human factor VIIa (rFVIIa) cleared principally by antithrombin following intravenous administration in hemophilia patients
-
Agersø H, Brophy DF, Pelzer H, Martin EJ, Carr M, Hedner U, Ezban M. Recombinant human factor VIIa (rFVIIa) cleared principally by antithrombin following intravenous administration in hemophilia patients. J Thromb Haemost 2011; 9: 333-8.
-
(2011)
J Thromb Haemost
, vol.9
, pp. 333-338
-
-
Agersø, H.1
Brophy, D.F.2
Pelzer, H.3
Martin, E.J.4
Carr, M.5
Hedner, U.6
Ezban, M.7
-
18
-
-
66149175575
-
Plasma elimination kinetics for factor VII are independent of its activation to factor VIIa and complex formation with plasma inhibitors
-
Petersen LC, Elm T, Ezban M, Krogh TN, Karpf DM, Steinø A, Olsen EH, Sørensen BB. Plasma elimination kinetics for factor VII are independent of its activation to factor VIIa and complex formation with plasma inhibitors. Thromb Haemost 2009; 101: 818-26.
-
(2009)
Thromb Haemost
, vol.101
, pp. 818-826
-
-
Petersen, L.C.1
Elm, T.2
Ezban, M.3
Krogh, T.N.4
Karpf, D.M.5
Steinø, A.6
Olsen, E.H.7
Sørensen, B.B.8
-
19
-
-
79960392729
-
Prolonged half-life of glycoPEGylated rFVIIa variants compared to native rFVIIa
-
Karpf DM, Sørensen BB, Hermit MB, Holmberg HL, Tranholm M, Bysted BV, Groth AV, Bjørn SE, Stennicke HR. Prolonged half-life of glycoPEGylated rFVIIa variants compared to native rFVIIa. Thromb Res 2011; 128: 191-5.
-
(2011)
Thromb Res
, vol.128
, pp. 191-195
-
-
Karpf, D.M.1
Sørensen, B.B.2
Hermit, M.B.3
Holmberg, H.L.4
Tranholm, M.5
Bysted, B.V.6
Groth, A.V.7
Bjørn, S.E.8
Stennicke, H.R.9
-
20
-
-
79955662245
-
GlycoPEGylated rFVIIa (N7-GP) has a prolonged hemostatic effect in hemophilic mice compared with rFVIIa
-
Holmberg H, Elm T, Karpf D, Tranholm M, Bjørn SE, Stennicke H, Ezban M. GlycoPEGylated rFVIIa (N7-GP) has a prolonged hemostatic effect in hemophilic mice compared with rFVIIa. J Thromb Haemost 2011; 9: 1070-2.
-
(2011)
J Thromb Haemost
, vol.9
, pp. 1070-1072
-
-
Holmberg, H.1
Elm, T.2
Karpf, D.3
Tranholm, M.4
Bjørn, S.E.5
Stennicke, H.6
Ezban, M.7
-
21
-
-
77954368872
-
Prolonged effect of GlycoPEGylated rFVIIa (40k-PEG-rFVIIa) in rabbits correlates to activity in plasma
-
Johansen PB, Bjørn SE, Agersø H, Thorup I, Hermit MB, Sørensen B, Stennicke HR, Ezban M, Tranholm M. Prolonged effect of GlycoPEGylated rFVIIa (40k-PEG-rFVIIa) in rabbits correlates to activity in plasma. Thromb Haemost 2010; 104: 157-64.
-
(2010)
Thromb Haemost
, vol.104
, pp. 157-164
-
-
Johansen, P.B.1
Bjørn, S.E.2
Agersø, H.3
Thorup, I.4
Hermit, M.B.5
Sørensen, B.6
Stennicke, H.R.7
Ezban, M.8
Tranholm, M.9
-
22
-
-
0035160476
-
Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation
-
Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH)
-
Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M; Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001; 86: 1327-30.
-
(2001)
Thromb Haemost
, vol.86
, pp. 1327-1330
-
-
Taylor Jr, F.B.1
Toh, C.H.2
Hoots, W.K.3
Wada, H.4
Levi, M.5
-
23
-
-
69249213501
-
Implementation of the ISTH classification of non-overt DIC in a thromboplastin induced rabbit model
-
Olrik Berthelsen L, Thuri Kristensen A, Wiinberg B, Tranholm M. Implementation of the ISTH classification of non-overt DIC in a thromboplastin induced rabbit model. Thromb Res 2009; 124: 490-7.
-
(2009)
Thromb Res
, vol.124
, pp. 490-497
-
-
Olrik Berthelsen, L.1
Thuri Kristensen, A.2
Wiinberg, B.3
Tranholm, M.4
-
24
-
-
84887557283
-
Safety and pharmacokinetics of a recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP) in healthy volunteers
-
Golor G, Bensen-Kennedy D, Haffner S, Easton R, Jung K, Moises T, Lawo JP, Joch C, Veldman A. Safety and pharmacokinetics of a recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP) in healthy volunteers. J Thromb Haemost 2013; 11: 1977-85.
-
(2013)
J Thromb Haemost
, vol.11
, pp. 1977-1985
-
-
Golor, G.1
Bensen-Kennedy, D.2
Haffner, S.3
Easton, R.4
Jung, K.5
Moises, T.6
Lawo, J.P.7
Joch, C.8
Veldman, A.9
-
25
-
-
0032465250
-
The effect of recombinant factor VIIa (NovoSeven) in healthy volunteers receiving acenocoumarol to an International Normalized Ratio above 2.0
-
Erhardtsen E, Nony P, Dechavanne M, Ffrench P, Boissel JP, Hedner U. The effect of recombinant factor VIIa (NovoSeven) in healthy volunteers receiving acenocoumarol to an International Normalized Ratio above 2.0. Blood Coagul Fibrinolysis 1998; 9: 741-8.
-
(1998)
Blood Coagul Fibrinolysis
, vol.9
, pp. 741-748
-
-
Erhardtsen, E.1
Nony, P.2
Dechavanne, M.3
Ffrench, P.4
Boissel, J.P.5
Hedner, U.6
-
26
-
-
0031926569
-
Population pharmacokinetics of recombinant factor VIIa in volunteers anticoagulated with acenocoumarol
-
Girard P, Nony P, Erhardtsen E, Delair S, Ffrench P, Dechavanne M, Boissel JP. Population pharmacokinetics of recombinant factor VIIa in volunteers anticoagulated with acenocoumarol. Thromb Haemost 1998; 80: 109-13.
-
(1998)
Thromb Haemost
, vol.80
, pp. 109-113
-
-
Girard, P.1
Nony, P.2
Erhardtsen, E.3
Delair, S.4
Ffrench, P.5
Dechavanne, M.6
Boissel, J.P.7
-
27
-
-
18944386159
-
A study of the pharmacokinetics and safety of recombinant activated factor VII in healthy Caucasian and Japanese subjects
-
Fridberg MJ, Hedner U, Roberts HR, Erhardtsen E. A study of the pharmacokinetics and safety of recombinant activated factor VII in healthy Caucasian and Japanese subjects. Blood Coagul Fibrinolysis 2005; 16: 259-66.
-
(2005)
Blood Coagul Fibrinolysis
, vol.16
, pp. 259-266
-
-
Fridberg, M.J.1
Hedner, U.2
Roberts, H.R.3
Erhardtsen, E.4
-
28
-
-
55749111387
-
The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics
-
Fishburn CS. The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics. J Pharm Sci 2008; 97: 4167-83.
-
(2008)
J Pharm Sci
, vol.97
, pp. 4167-4183
-
-
Fishburn, C.S.1
-
29
-
-
0033654389
-
Modulation of the pharmacokinetics and pharmacodynamics of proteins by polyethylene glycol conjugation
-
Mehvar R. Modulation of the pharmacokinetics and pharmacodynamics of proteins by polyethylene glycol conjugation. J Pharm Sci 2000; 3: 125-36.
-
(2000)
J Pharm Sci
, vol.3
, pp. 125-136
-
-
Mehvar, R.1
-
30
-
-
79959828057
-
Safety and pharmacokinetics of a glycoPEGylated recombinant activated factor VII derivative: a randomized first human dose trial in healthy subjects
-
Møss J, Rosholm A, Laurén A. Safety and pharmacokinetics of a glycoPEGylated recombinant activated factor VII derivative: a randomized first human dose trial in healthy subjects. J Thromb Haemost 2011; 9: 1368-74.
-
(2011)
J Thromb Haemost
, vol.9
, pp. 1368-1374
-
-
Møss, J.1
Rosholm, A.2
Laurén, A.3
-
31
-
-
84893582243
-
-
Novo Nordisk press release. Accessed April
-
Novo Nordisk press release. www.novonordisk.com/images/investors/investor_presentations/2011/Q3/PR111027_9M_2011_UK.pdf. Accessed April 2013
-
(2013)
-
-
-
32
-
-
84893577086
-
-
Bayer press release. Accessed May
-
Bayer press release. www.investor.bayer.com/news/investor-news/investor-news/showNewsItem/1567/1367589360/98b78129e8/. Accessed May 2013
-
(2013)
-
-
-
33
-
-
84873062146
-
Enhanced pharmacokinetics of factor VIIA as a monomeric FC fusion
-
Salas J, Liu T, Kistanova E, Ashworth T, Slein M, Patel R, Kamphaus G, Correia A, Bitonti A, Dallabrida S, Jiang H, Peters R. Enhanced pharmacokinetics of factor VIIA as a monomeric FC fusion. J Thromb Haemost 2011; 9(Suppl. 2): 268.
-
(2011)
J Thromb Haemost
, vol.9
, Issue.SUPPL. 2
, pp. 268
-
-
Salas, J.1
Liu, T.2
Kistanova, E.3
Ashworth, T.4
Slein, M.5
Patel, R.6
Kamphaus, G.7
Correia, A.8
Bitonti, A.9
Dallabrida, S.10
Jiang, H.11
Peters, R.12
|